Comparative Pharmacology
Head-to-head clinical analysis: BIORPHEN versus GABAPENTIN ENACARBIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BIORPHEN versus GABAPENTIN ENACARBIL.
BIORPHEN vs GABAPENTIN ENACARBIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Biorphen (phenylephrine) is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction and increased blood pressure.
Gabapentin enacarbil is a prodrug of gabapentin. It binds to the α2δ subunit of voltage-gated calcium channels, inhibiting calcium influx and reducing release of excitatory neurotransmitters such as glutamate, norepinephrine, and substance P. This modulates neuronal excitability and pain transmission.
Adults: 2.5-10 mg IV/IM/SC every 2-4 hours as needed for pain; oral: 10-20 mg every 4 hours as needed.
Initial: 600 mg orally once daily; titrate to 600 mg three times daily; max 2400 mg/day divided three times daily.
None Documented
None Documented
Clinical Note
moderateGabapentin enacarbil + Venlafaxine
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Venlafaxine."
Clinical Note
moderateGabapentin enacarbil + Nefazodone
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Nefazodone."
Clinical Note
moderateGabapentin enacarbil + Stiripentol
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Stiripentol."
Clinical Note
moderateTerminal elimination half-life: 2–4 hours (short-acting opioid; context: requires q4h dosing for sustained analgesia).
Terminal half-life of gabapentin: 5–7 hours in patients with normal renal function. Renal impairment prolongs half-life proportionally to creatinine clearance decline.
Renal: 90% as glucuronide conjugates; Fecal: 10% (unabsorbed/biliary).
Renal: 100% as unchanged gabapentin (prodrug is rapidly hydrolyzed to gabapentin after absorption). No biliary or fecal elimination of active drug.
Category C
Category A/B
Anticonvulsant
Anticonvulsant
Gabapentin enacarbil + Pomalidomide
"The risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with Pomalidomide."